Check out Windlas Biotech IPO GMP aka IPO Grey Market Premium, Kostak rates, and Subject to Sauda rates as of today. Windlas Biotech IPO GMP is gone down to a 85 level.
Windlas Biotech IPO to hit the market on 04 August 2021 and closes on 06 August 2021 as the dates are officially announced in RHP. The company to raise ₹401.654 crore via IPO that comprises ₹165 crore via fresh issue and offer for sale will be 5,142,067 shares. They are one of the leading companies in pharmaceutical formulations contract development and manufacturing organizations (CDMO) segment in India. Some of their client base includes big names like Pfizer Ltd, Sanofi India Ltd, Cadila Healthcare Ltd, Emcure Pharmaceuticals Ltd, Eris Lifesciences Ltd, Intas Pharmaceuticals Ltd and Systopic Laboratories Private Limited. The IPO price band is fixed at ₹448 to ₹460. The Windlas Biotech IPO to list on NSE and BSE.
What is Windlas Biotech IPO GMP Today?
The Windlas Biotech IPO GMP aka grey market premium is ₹85.
What is Windlas Biotech IPO Kostak Rates Today?
The Windlas Biotech IPO kostak rate is ₹0.
What is Windlas Biotech IPO Subject to Sauda Price Today?
The Windlas Biotech IPO subject to sauda rates is ₹0.
Windlas Biotech IPO Expected Returns?
The Windlas Biotech expected return is 20%.
Windlas Biotech IPO GMP Rates day by day with Kotak rates.
About Windlas Biotech
We employ 954 employees at our four state-of-the-art manufacturing facilities in Dehradun, Uttarakhand India. We also have a salesforce and distribution network spread across 14 states. We market our own manufactured authentic nutraceutical, pharmaceutical and ayurvedic products to serve the semi-urban and rural communities at affordable prices. “The registered name of the company is Windlas Biotech Limited (Formerly known as Windlas Biotech Private Limited).”
Innovation is at the core of our spirit at Windlas. We aim to deliver customized, innovative and complex generic products to our customers. Our R&D team work closely with customers or prospective customers, and provide innovative and cost efficient solutions tailored to meet specific customer requirements. When we work on a customer specific project then the customers also oversees the planning and execution of our projects. Our R&D team oversees the transfer of technology from lab scale to plant scale and prepares back-up strategies. Thereafter, we scale-up our operations from the R&D stage to large-scale manufacturing. We emphasize on maintaining consistency in the quality of our products as well as planning and executing projects in a timely manner.
We are constantly focused on improving efficiency of our operations and increasing the value of our research and manufacturing services to our clients. We are proud of our undeterred focus on quality and compliance assurance systems that provide authentic, efficacious and safe products to all patients consuming our products. Our dedication to quality can be seen from the fact that almost 40% of our staff workforce is in Quality Control / Quality Assurance functions.
Windlas Biotech IPO Date & Price Band
|IPO Open:|| 04 August 2021
|IPO Close:|| 06 August 2021
|IPO Size:||Approx ₹401.54 Crores|
|Fresh Issue:||Approx ₹165 Crores|
|Offer for Sale:|| Approx ₹236.54 Crores - 5,142,067 Equity Shares
|Face Value:||₹5 Per Equity Share|
|Price Band:||₹448 to ₹460 Per Share|
|Listing on:||BSE & NSE|
Windlas Biotech IPO Market Lot
|Minimum Lot Size:||Minimum 30 Shares|
|Maximum Lot Size:||Maximum 420 Shares|
Windlas Biotech IPO Date, Time Table, Allotment & Listing
|Price Band Announcement:|| 30 July 2021
|Anchor Investors Allotment:|| 03 August 2021
|IPO Open Date:|| 04 August 2021
|IPO Close Date:|| 06 August 2021
|Basis of Allotment:|| 11 August 2021
|Refunds:|| 12 August 2021
|Credit to Demat Account:|| 13 August 2021
|IPO Listing Date:|| 17 August 2021
Windlas Biotech IPO GMP aka Grey Market Premium FAQs:
- IPO Grey Market Premium (Windlas Biotech IPO GMP) mention is valid for the specific date as mentioned in the header.
- We are not buying and selling IPO forms on IPO Grey Market.
- Kostak Rate is the premium one gets by selling his/her IPO application (in an off-market transaction) to someone else even before allotment or listing of the issue.
- Do not subscribe for IPO by just seeing premium Price as it may change anytime before listing. Subscribe only considering Fundamental of the companies.